Russia and Nigeria have agreed to develop cooperation in the production of pharmaceuticals, including vaccines, following a BRICS Women’s Business Alliance mission to Abuja. The news was reported to TASS by Lyudmila Shcherbakova, President of the Wellfarm Group and a member of the Russian delegation.
“Based on the results of the business mission, we reached an agreement on developing the production of Russian pharmaceutical products, including vaccines. At the first stage, Nigerian specialists will undergo training at Russian facilities. We also received from our colleagues in Abuja a list of the most in-demand medicines, which will allow us to move on to practical implementation,” she said.
Shcherbakova noted that the Nigerian market—and the African continent as a whole—has enormous potential. Nigeria is one of Africa’s largest economies and its most populous nation. The country faces a high burden of infectious diseases and a growing prevalence of noncommunicable illnesses, which drives strong demand for affordable, high-quality medicines, she explained.
According to her, the most promising markets for the Russian pharmaceutical industry are BRICS members and other rapidly growing economies characterized by expanding populations, rising healthcare spending, and interest in diversifying suppliers. These include BRICS+ countries (especially Africa and the Middle East) and Southeast Asia—Vietnam, Indonesia, and the Philippines. Markets such as Brazil, Mexico, and Argentina are also of strategic interest, Shcherbakova added.
GSV "Russia - Islamic World"
Photo: Federation Council
Based on materials from TASS